We are live on ! Find out more

Krystal Biotech

KRYS

Market cap $10.1B

342.69 USD

-4.31

1.24%

At close Updated Sep 14, 11:24 AM EDT

1 day

-1.24%

5 days

-2.23%

1 month

3.14%

3 months

5.52%

6 months

36.99%

Year to date

38.79%

1 year

120.08%

5 years

508.9%

10 years

3,120.77%

About: Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Employees: 295

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60%

Neutral 40%

Negative 0%

Zacks Investment Research

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

Zacks Investment Research

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Investors Business Daily

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.

Krystal Biotech Q2 Earnings Call Highlights

Zacks Investment Research

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Krystal Biotech: International Expansion And A Vibrant Pipeline

Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS's pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.

Krystal Biotech: International Expansion And A Vibrant Pipeline

See News Rankings

Price charts implemented using Lightweight Charts™